To mitigate these risks, research is shifting toward localized delivery, cell-type-specific targeting, and phase-selective inhibition, especially relevant in diseases like myocardial infarction, aortic dissection, and stroke, where C3 exerts temporally distinct roles. This evidence concerns the gene C3 and myocardial infarction.